BiotechTube

Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV. + Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine. + Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Invasive Meningococcal Disease

Conditions

Invasive Meningococcal Disease

Trial Timeline

Aug 1, 2011 → Sep 1, 2012

NCT ID
NCT01272180

About Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV. + Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine. + Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.

Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV. + Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine. + Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV. is a phase 2 stage product being developed by Novartis for Invasive Meningococcal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01272180. Target conditions include Invasive Meningococcal Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01272180Phase 2Completed

Competing Products

20 competing products in Invasive Meningococcal Disease

See all competitors
ProductCompanyStageHype Score
BSG005Alkem LaboratoriesPhase 1/2
41
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
51
Trastuzumab deruxtecan + DurvalumabDaiichi SankyoPhase 2
52
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
77
Micafungin + fluconazoleAstellas PharmaPhase 3
77
MicafunginAstellas PharmaPre-clinical
23
Micafungin (Mycamine)Astellas PharmaPhase 1
33
Pudexacianinium chlorideAstellas PharmaPhase 2
52
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
52
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
52
Isavuconazonium sulfate + Voriconazole + PosaconazoleAstellas PharmaPre-clinical
23
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
77
Isavuconazonium sulfate + Isavuconazonium sulfateAstellas PharmaPhase 2
52
Micafungin + Systemic antifungal therapyAstellas PharmaPhase 2
52
MicafunginAstellas PharmaPre-clinical
23
Micafungin + PlaceboAstellas PharmaPhase 3
77
MicafunginAstellas PharmaApproved
85
Olorofim + AmBisome®ShionogiPhase 3
77
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
77
SHR-A1811 + Trastuzumab EmtansineJiangsu Hengrui MedicinePhase 3
77

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85